NEETA BALKRISHAN AMIN
Pharmacy in Norristown, PA
License number
Michigan 5302031072
Issued Date
Dec 10, 1996
Expiration Date
Jun 30, 2003
Category
Pharmacy
Type
Pharmacist
Address
Address
Norristown, PA 19401
Professional information
Use Of 5Ht4 Receptor Antagonists In The Prophylaxis Or Treatment Of Certain Cardiovascular Conditions
US Patent:
2008012, May 29, 2008
Filed:
Oct 31, 2007
Appl. No.:
11/930277
Inventors:
Mireille Marguerite Jeanne Bonhomme - Les Ulis, FR
Antoine Michel Alain Bril - Suresnes, FR
Bernard Emile Joseph Gout - Rennes, FR
Bela Rajiv Patel - King of Prussia PA, US
Gillian Louise Shepherd - Twickenham, GB
Neeta Balkrishan Amin - King of Prussia PA, US
Bernard Enno Ilson - Philadelphia PA, US
Antoine Michel Alain Bril - Suresnes, FR
Bernard Emile Joseph Gout - Rennes, FR
Bela Rajiv Patel - King of Prussia PA, US
Gillian Louise Shepherd - Twickenham, GB
Neeta Balkrishan Amin - King of Prussia PA, US
Bernard Enno Ilson - Philadelphia PA, US
International Classification:
A61K 31/5365, A61P 9/00
US Classification:
5142302
Abstract:
The invention relates to the use of a 5-HTreceptor antagonist in the manufacture of a medicament for the prophylaxis or treatment of atrial remodelling in a mammal. Preferably, the antagonist is N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) or a pharmaceutically acceptable salt thereof.The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of atrial fibrillation in a mammal by administering to the mammal a daily oral or parenteral dosage regimen of about 0.2 mg to 1.0 mg of the SB 207266 or salt thereof per kg of total body weight (measured as the free base).The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the prophylaxis or treatment of atrial arrhythmia in a mammal by administration of the SB 207266 or salt thereof on the first day at a loading dose of about 1.2 to about 2.0 times the daily maintenance dose, followed by administration of the SB 207266 or salt at the daily maintenance dose on subsequent days.
Use Of 5Ht4 Receptor Antagonists In The Prophylaxis Or Treatment Of Certain Cardiovascular Conditions
US Patent:
2007001, Jan 18, 2007
Filed:
Sep 20, 2006
Appl. No.:
11/533542
Inventors:
Mireille Bonhomme - Les Ulis, FR
Antoine Bril - Les Ulis, FR
Bernard Gout - Les Ulis, FR
Bela Patel - King of Prussia PA, US
Gillian Shepherd - Twickenham, GB
Neeta Amin - King of Prussia PA, US
Bernard Ilson - Philadelphia PA, US
Antoine Bril - Les Ulis, FR
Bernard Gout - Les Ulis, FR
Bela Patel - King of Prussia PA, US
Gillian Shepherd - Twickenham, GB
Neeta Amin - King of Prussia PA, US
Bernard Ilson - Philadelphia PA, US
International Classification:
A61K 31/4965
US Classification:
514255030
Abstract:
The invention relates to the use of a 5-HTreceptor antagonist in the manufacture of a medicament for the prophylaxis or treatment of atrial remodelling in a mammal. Preferably, the antagonist is N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) or a pharmaceutically acceptable salt thereof. The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of atrial fibrillation in a mammal by administering to the mammal a daily oral or parenteral dosage regimen of about 0.2 mg to 1.0 mg of the SB 207266 or salt thereof per kg of total body weight (measured as the free base). The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the prophylaxis or treatment of atrial arrhythmia in a mammal by administration of the SB 207266 or salt thereof on the first day at a loading dose of about 1.2 to about 2.0 times the daily maintainance dose, followed by administration of the SB 207266 or salt at the daily maintainance dose on subsequent days.